Welcome to CDC Stacks | Guidelines for Designing Rapid Assessment Surveys of HIV Seroprevalence among Hospitalized Patients. Centers for Disease Control and Prevention - 7363 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Guidelines for Designing Rapid Assessment Surveys of HIV Seroprevalence among Hospitalized Patients. Centers for Disease Control and Prevention
  • Published Date:
    January-February 1994
  • Status:
    retired
  • Source:
    Public health reports (Washington, D.C. : 1974). 109(1):53-9.
Filetype[PDF - 1.25 MB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    The most effective means of preventing human immunodeficiency virus (HIV) infection is preventing exposure. The provision of antiretroviral drugs to prevent HIV infection after unanticipated sexual or injection-drug--use exposure might be beneficial. The U.S. Department of Health and Human Services (DHHS) Working Group on Nonoccupational Post exposure Prophylaxis (nPEP) made the following recommendations for the United States. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person known to be HIV infected, when that exposure represents a substantial risk for transmission, a 28-day course of highly active antiretroviral therapy (HAART) is recommended. Antiretroviral medications should be initiated as soon as possible after exposure. For persons seeking care < or =72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person of unknown HIV status, when such exposure would represent a substantial risk for transmission if the source were HIV infected, no recommendations are made for the use of nPEP. Clinicians should evaluate risks and benefits of nPEP on a case-by-case basis. For persons with exposure histories that represent no substantial risk for HIV transmission or who seek care >72 hours after exposure, DHHS does not recommend the use of nPEP. Clinicians might consider prescribing nPEP for exposures conferring a serious risk for transmission, even if the person seeks care >72 hours after exposure if, in their judgment, the diminished potential benefit of nPEP outweighs the risks for transmission and adverse events. For all exposures, other health risks resulting from the exposure should be considered and prophylaxis administered when indicated. Risk-reduction counseling and indicated intervention services should be provided to reduce the risk for recurrent exposures.

  • Document Type:
  • Supporting Files:
    No Additional Files
  1. Source:
    Description:
    Status:
    File Type:
You May Also Like: